Premium
β‐chemokine receptor expression in idiopathic inflammatory myopathies
Author(s) -
De Paepe Boel,
De Bleecker Jan L.
Publication year - 2005
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.20294
Subject(s) - polymyositis , ccr2 , chemokine receptor , chemokine , inflammation , cc chemokine receptors , dermatomyositis , receptor , myositis , ccl13 , downregulation and upregulation , immunology , inclusion body myositis , medicine , pathology , biology , biochemistry , gene
β‐chemokines attract and activate T cells and monocytes and have a key role in chronic inflammation. Certain β‐chemokines, such as monocyte chemoattractant protein‐1 (MCP‐1), have been reported to be upregulated in the idiopathic inflammatory myopathies (IIM). We studied the distribution of β‐chemokine receptors in polymyositis (PM), sporadic inclusion‐body myositis (sIBM), dermatomyositis (DM), and control samples. CCR1–5 were localized to blood vessels in all samples. In addition, increased endothelial expression of CCR2A was observed in IIM. Subsets of inflammatory cells, identified as macrophages and T cells, in all three types of IIM expressed CCR2A, CCR2B, CCR3, CCR4, and CCR5. In contrast to an earlier report, we found CCR2B to be the most prominent MCP‐1 receptor on inflammatory cells in IIM, especially in PM and sIBM. Strong CCR4 expression was present on myonuclei of regenerating muscle fibers. The prominence of the CCR2 receptors further underlines the importance of the interaction with their ligand MCP‐1 in the immunopathogenesis of IIM and puts CCR2B forward as a potential target for future therapeutic intervention. Muscle Nerve, 2005